Tumors in patients over 65 years of age exhibit significantly higher PDGFA expression levels than those in younger individuals do, with an increased PDGFA/PDGFRA expression ratio.141 In contrast, pediatric GBM patients show a greater prevalence of PDGFRA amplification than adult GBM patients do.142 This amplification is notably associated with tumors affecting the corpus callosum and is frequently linked to the aggressive H3K27M mutation found in diffuse midline gliomas.143 Despite its frequent occurrence, the prognostic significance of PDGFRA amplification remains uncertain. Here, PDGFA is linked to diffuse midline glioma.